Adolor Corporation to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
March 14 2008 - 8:30AM
Business Wire
Adolor Corporation (Nasdaq:ADLR) announced that it will participate
in the Lehman Brothers Eleventh Annual Global Healthcare Conference
in Miami, FL. The company�s presentation is scheduled for 10:15
a.m. (ET) on Wednesday, March 19, 2008. Michael R. Dougherty,
president and chief executive officer, will present an overview of
the company. A live and on-demand webcast of the presentation will
be accessible on the company's website, http://www.adolor.com, in
the "Investor Insights" section during the presentation, and replay
of the presentation, including PowerPoint slides, will be available
within 24 hours of the live presentation. About Adolor Corporation
Adolor Corporation (Nasdaq:ADLR) is a biopharmaceutical company
specializing in the discovery, development and commercialization of
novel prescription pain management products. Adolor has two lead
product candidates in development: Entereg� (alvimopan) for the
management of the gastrointestinal side effects associated with
opioid use; and, novel Delta opioid receptor agonists for a variety
of pain indications. Adolor and GlaxoSmithKline are collaborating
in the worldwide development and commercialization of Entereg in
multiple indications. Adolor and Pfizer are collaborating in the
worldwide development and commercialization of two Delta agonists
for pain. Adolor also has a number of discovery research programs
focused on the identification of novel compounds for the treatment
of pain. By applying its knowledge and expertise in pain
management, along with ingenuity, Adolor is seeking to make a
positive difference for patients, caregivers and the medical
community. For more information, visit www.adolor.com. This
release, and oral statements made with respect to information
contained in this release, may constitute forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include those
which express plan, anticipation, intent, contingency, goals,
targets or future development and/or otherwise are not statements
of historical fact. These statements are based upon management's
current expectations and are subject to risks and uncertainties,
known and unknown, which could cause actual results and
developments to differ materially from those expressed or implied
in such statements. Such known risks and uncertainties relate to,
among other factors: the risk that Adolor may not receive
regulatory approval of ENTEREG � (alvimopan) for POI, OBD, or any
other indication; the risk that the PDUFA date extended to May 10,
2008 is further extended or not met; the risk that a risk
management plan acceptable to the FDA could materially adversely
affect the commercial prospects for ENTEREG, if regulatory approval
is achieved; the risk that Adolor may not be able to adequately
address the deficiencies in the November 2006 FDA approvable
letter; the risk that Adolor may not obtain FDA approval for
ENTEREG in POI, whether due to Adolor's inability to provide
additional data satisfactory to the FDA to obtain approval for the
NDA, the adequacy of the safety and efficacy data from all of the
ENTEREG studies, changing regulatory requirements, the risk that
the FDA may not agree with Adolor's and GSK's analyses of the
ENTEREG studies (including Study 014) and may evaluate the results
of these studies by different methods or conclude that the results
from the studies, whether or not statistically significant, do not
support safety, efficacy, a favorable risk/benefit profile, or
there were human errors in the conduct of the studies, or
otherwise; adverse safety findings in any ENTEREG studies; the risk
that the alvimopan Investigational New Drug Applications (INDs)
remain on clinical hold indefinitely; the risk that filing targets
for regulatory submissions or user fee goal dates are not met; the
risk that the results of other clinical trials of Adolor's drug
product candidates, including our Delta product candidates are not
positive; the risk of product liability claims; reliance on third
party manufacturers; the costs, delays and uncertainties inherent
in scientific research, drug development, clinical trials and the
regulatory approval process; Adolor's history of operating losses
since inception and its need for additional funds to operate its
business; Adolor's reliance on its collaborators, including GSK and
Pfizer, respectively in connection with the development and
commercialization of product candidates; market acceptance of
Adolor's products, if regulatory approval is achieved; competition;
and securities litigation. Further information about these and
other relevant risks and uncertainties may be found in Adolor's
Reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities
and Exchange Commission. Adolor urges you to carefully review and
consider the disclosures found in its filings which are available
in the SEC EDGAR database at http://www.sec.gov and from Adolor at
http://www.adolor.com. Given the uncertainties affecting
pharmaceutical companies in the development stage, you are
cautioned not to place undue reliance on any such forward-looking
statements, any of which may turn out to be wrong due to inaccurate
assumptions, unknown risks, uncertainties or other factors. Adolor
undertakes no obligation to (and expressly disclaims any such
obligation to) publicly update or revise the statements made herein
or the risk factors that may relate thereto whether as a result of
new information, future events, or otherwise. This press release is
available on the website http://www.adolor.com.
Adolor Corp. (MM) (NASDAQ:ADLR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adolor Corp. (MM) (NASDAQ:ADLR)
Historical Stock Chart
From Jul 2023 to Jul 2024